The Role of Rituximab in Lymphomas

The Role of Rituximab in Lymphomas

Over the last years the treatment of non-Hodgkin's lymphoma underwent a great advance in relation to the diagnosis, classification, high-dose chemotherapy, and hematopoietic stem cell transplantation. Simultaneously with this, there was the development of new drugs and support therapy which ena...

Full description

Bibliographic Details
Main Author:	Bertrand Coiffier
Format:	Article
Language:	English
Published:	Elsevier 2002-01-01
Series:	Revista Brasileira de Hematologia e Hemoterapia
Subjects:	Non-Hodgkin's Lymphoma monoclonal antibodies CD-antigen Rituximab
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842002000300004&tlng=en

Similar Items

The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma
by: K D Kaplanov, et al.
Published: (2014-06-01)

Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment
by: Letizia Polito, et al.
Published: (2013-10-01)

Immunotherapy in indolent Non-Hodgkin's Lymphoma
by: Ghid Amhaz, et al.
Published: (2022-01-01)

Rituximab for primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp
by: Čolović Nataša, et al.
Published: (2008-01-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Combined chemoimmunotherapy of patients with mature B-cell non-Hodgkin lymphomas age group until 18 years: results of multicenter study NHL 2004 m with rituximab and modified B-NHL BFM 90 protocol applications
by: E. V. Samochatova, et al.
Published: (2022-11-01)

Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells
by: Eleonora Vecchio, et al.
Published: (2024-02-01)

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
by: Timothy M. Pierpont, et al.
Published: (2018-06-01)

Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response
by: Dhon Roméo Makanga, et al.
Published: (2021-01-01)

Rituximab-induced interstitial pneumonitis in patient with non-Hodgkin lymphoma: a clinical case
by: Nikolai A. Ognerubov, et al.
Published: (2022-08-01)

Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
by: Vibor Milunović, et al.
Published: (2017-01-01)

Linfoma hepático primario: Evolución favorable con quimioterapia combinada con rituximab Primary hepatic lymphoma: favorable outcome with chemotherapy plus rituximab
by: I. Serrano-Navarro, et al.
Published: (2008-11-01)

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
by: Ruben Van Dijck, et al.
Published: (2021-04-01)

Use of rituximab in NHL malt type pregnant in I° trimester for two times
by: Sica Antonello, et al.
Published: (2019-11-01)

Radioimmunotherapy of lymphoma
by: Goldsmith Stanley J.
Published: (2012-01-01)

Rituximab: historia, farmacología y perspectivas Rituximab: history, pharmacology and perspectives
by: Edgardo E. Espinosa Estrada, et al.
Published: (2010-12-01)

Does Gender Matter in Non-Hodgkin Lymphoma? Differences in Epidemiology, Clinical Behavior, and Therapy
by: Nurit Horesh, et al.
Published: (2014-10-01)

Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study
by: David Belada, et al.
Published: (2007-01-01)

Current approaches to the treatment of non-Hodgkin's lymphoma
by: Christian Gisselbrecht
Published: (2011-10-01)

Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis
by: Tianyu Si, et al.
Published: (2023-12-01)

Successful Rapid Desensitization of Two Teenagers with Rituximab Hypersensitivity
by: Murat Cansever, et al.
Published: (2019-05-01)

Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma
by: Caroline eBodet-Milin, et al.
Published: (2013-07-01)

Evolution of immunobiological changes and their significance for the treatment of patients with Non-Hodgkin’s lymphoma
by: Aliona NICORICI
Published: (2019-06-01)

Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review
by: Deirdre Kelly, MBBCH, et al.
Published: (2016-09-01)

Anti-CD20 monoclonal antibodies: reviewing a revolution
by: J. M. L. Casan, et al.
Published: (2018-12-01)

Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
by: Murat Özbalak, et al.
Published: (2022-11-01)

A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL)
by: Mayur Narkhede, et al.
Published: (2023-05-01)

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab
by: Gianpaolo Marcacci, et al.
Published: (2021-06-01)

Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma
by: Mihaljević Biljana, et al.
Published: (2008-01-01)

A case report of hepatitis B virus reactivation 19 months after cessation of chemotherapy with rituximab
by: Xiangjuan Guo, et al.
Published: (2022-12-01)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
by: Sonia Boyer-Suavet, et al.
Published: (2020-01-01)

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
by: Natalie S. Grover, et al.
Published: (2015-09-01)

Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's lymphoma
by: Roiya Farhan, MBBS, et al.
Published: (2020-12-01)

Rituximab Therapy for Treatment of Pemphigus in Southeast Asians
by: Kanokrungsee S, et al.
Published: (2021-04-01)

Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra
by: K. A. Sychevskaya, et al.
Published: (2022-04-01)

Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice
by: Rita Tavarozzi, et al.
Published: (2023-11-01)

Inutility of IMP3 Marker in Differentiating Hodgkin Lymphoma from Large Cell Lymphoma
by: Ali Zare Mehrjerdi, et al.
Published: (2020-08-01)

Fate of 177Lu-CHX-A”-DTPA-Rituximab: In vitro Evaluation in Raji Cell Line
by: Saloni Arun Samant, et al.
Published: (2023-01-01)

Cold Autoimmune Hemolytic Anemia due to High-grade non Hodgkin's B cell Lymphoma with Weak Response to Rituximab and Chemotherapy Regimens
by: Behzad Nazel Khosroshahi, et al.
Published: (2015-09-01)